Pharmacokinetic-pharmacodynamic modelling of danofloxacin in Turkeys

Veterinary Research Communications

Volumn 30, Issue 7, 2006, Pages 775-789

  Haritova, A M ^a   Rusenova, N V ^a   Parvanov, P R ^a   Lashev, L D ^a   Fink Gremmels, J ^b  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Danofloxacin; Pharmacokinetic pharmacodynamic modelling; Turkeys

Indexed keywords

ANTIBIOTIC AGENT; DANOFLOXACIN;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BODY WEIGHT; BREEDING; CLINICAL STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; EX VIVO STUDY; EXPERIMENTAL MODEL; FEMALE; MALE; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TURKEY (BIRD);

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; POULTRY DISEASES; TURKEYS;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 33749251868     PISSN: 01657380     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11259-006-3400-7     Document Type: Article

References (41)

1. Aliabadi, F.S. and Lees, P., 2001. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. American Journal of Veterinary Research, 62, 1979-1989
2. Aliabadi, F.S. and Lees, P., 2002. Pharmacokinetics and pharmacokinetic/ pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics, 25, 161-174
3. Aliabadi, F.S. and Lees, P., 2003. Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf. Research in Veterinary Science, 74, 247-259.
4. Aliabadi, F.S., Ali, B.H., Landoni, M.F. and Lees, P., 2003a. Pharmacokinetics and Pk/Pd modelling of danofloxacin in camel serum and tissue cage fluids. The Veterinary Journal, 165, 104-118
5. Aliabadi, F.S., Landoni, M.F. and Lees, P., 2003b. Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids. Antimicrobial Agents and Chemotherapy, 47, 623-635
6. Anadán, A., Martinez-Larranaga, M.R., Diaz, M.J., Fernandez-Cruz, M.L., Frejo, M.T., Fernandez, M. and Morales, M.E., 1997. Lung tissue concentrations and plasma pharmacokinetics of danofloxacin following oral administration to broiler chickens. Journal of Veterinary Pharmacology and Therapeutics, 20 (supplement 1), 197-198
7. Bauditz, R., 1987. Results of clinical studies with Baytril in poultry. Veterinary Medical Review. 2, 130-136
8. Behr, K.-P., Friederichs, M., Hinz, K.-H., Luders, H. and Siegmann, O., 1988. Klinische Erfahrungen mit dem Chemotherapeutikum Enrofloxacin in Huhner- und Putenherden. Tierarztliche Umschau, 43, 507-515
9. Brown, S.A., 1996. Fluoroquinolones in animal health. Journal of Veterinary Pharmacology and Therapeutics, 19, 1-14
10. Chansiripornchai, N. and Sasipreeyajan, J., 2002. Efficacy of sarafloxacin in broilers after experimental infection with Escherichia coli. Veterinary Research Communications, 26, 255-262
11. Charleston, B., Gate, J.J., Aitken, I.A., Stephan, B. and Froyman, R., 1998. Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens. Antimicrobial Agents and Chemotherapy, 42, 83-87
12. Drusano, G.L., 2000. Fluoroquinolone pharmacodynamics: Prospective determination of relationships between exposure and outcome. Journal of Chemotherapy, 12 (supplement 4), 21-26
13. Dorestein, G.M., 1999. Metabolic considerations for treatment of birds. In: Proceedings of International Virtual} Conferences in Veterinary Medicine: Diseases of Exotic Animals and Wildlife. http://www.vet.uga.edu/ivcvm/1999/INDEX.htm
14. el-Gendi, A.Y., el-Banna, H.A., Abo Norag, M. and Gaber, M., 2001. Disposition kinetics of danofloxacin and ciprofloxacin in broiler chickens. Deutsche Tierarztliche Wochenschrift, 108, 429-434
15. EMEA/CVMP/342/99-Final, 1999. Antibiotic resistance in the European Union associated with therapeutic use of veterinary medicines. Report and qualitative risk assessment by the Committee for Veterinary Medicinal Products
16. EU, 2003. Opinion of the scientific committee on veterinary measures relating to public health on the human health risk caused by the use of fluoroquinolones in animals (adopted 26-27 March 2003), EC, Directorate C - Scientific Opinions, http://europa.eu.int/comm/food/fs/sc/scv/ outcome_en.html
17. Fiorentin, L., Soncini, R.A., da Costa, J.L.A., Mores, M.A.Z., Trevisol, I.M., Toda, M. and Vieira, N.D., 2003. Apparent eradication of Mycoplasma synoviae in broiler breeders subjected to intensive antibiotic treatment directed to control Escherichia coli. Avian Pathology, 32, 213-216
18. Garcia, M.A., Solans, C., Aramayona, J.J., Rueda, S. and Bregante, M.A., 2000. Development of a method for the determination of danofloxacin in plasma by HPLC with fluorescence detection. Biomedical Chromatography, 14, 89-92
19. Gibaldi, M. and Perrier, D., 1982. Pharmacokinetics, 2nd edn, (Marcel Dekker, NY)
20. Giraud, E., Leroy-Setrin, S., Flaujac, G., Cloeckaert, A., Dho-Moulin, M. and Chaslus-Dancla, E., 2001. Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys. Journal of Antimicrobial Chemotherapy, 47, 341-343
21. Hafez, H.M., Emele, J. and Woernle, H., 1990. Turkey rhinotracheitis (TRT). Serological flock profiles and economic parameters and treatment trials using enrofloxacin (Baytril). Tierarztliche Umschau, 45, 111-114
22. Johnson, J.R., Murray, A.C., Gajewski, A., Sullivan, M., Snippes, P., Kuskowski, M.A. and Smith, K.E., 2003. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products. Antimicrobial Agents and Chemotherapy, 47, 2161-2168
23. Johnson, J.R., van der Schee, C., Kuskowski, M.A., Goessens, W. and Belkum, A., 2002. Phylogenetic background and virulence profiles of fluoroquinolone-resistant clinical Escherichia coli isolates from The Netherlands. The Journal of Infectious Diseases, 186, 1852-1856
24. Khac, S.B.P., Truong, Q.C., Lafont, J.P., Gutmann, L., Zhou, X.Y,. Osman, M. and Moreau, N.J., 1996. Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Antimicrobial Agents and Chemotherapy, 40, 1504-1507
25. Knoll, U., Glunder, G. and Kietzmann, M., 1999. Comparative study of the pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. Journal of Veterinary Pharmacology and Therapeutics, 22, 239-246
26. Lees, P. and Aliabadi, F.S., 2002. Rational dosing of antimicrobial drugs: Animal versus humans. International Journal of Antimicrobial Agents, 19, 269-284
27. Meibohm, B. and Derendorf, H., 2002. Pharmacokinetic-pharmacodynamic studies in drug product development. Journal of Pharmaceutical Sciences, 91, 18-31
28. Raemdonck, D.L., Tanner, A.C., Tolling, S.T. and Michener, S.L., 1992. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials. Avian Diseases, 36, 964-967
29. Russo, T.A., and Johnson, J.R., 2003. Medical and economic impact of extraintestinal infections due to Escherichia coli: An overlooked epidemic. Microbes and Infection. 5, 449-456
30. Sarasola, P., Lees, P., Aliabadi, F.S., McKellar, Q.A., Donachie, W., Marr, K.A., Sunderland, S.J. and Rowan, T.G., 2002. Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. Antimicrobial Agents and Chemotherapy, 46, 3013-3019
31. Scaglione, F., 2002. Can PK/PD be used in everyday clinical practice. International Journal of Antimicrobial Agents, 19, 349-353
32. Schentag, J.J., Gilliland, K.K. and Paladino, J.A., 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clinical Infectious Diseases, 32 (supplement 1), S39-S46
33. Sumano, L.H., Gutierrez, O.L. and Zamora, Q.M., 2003. Strategic administration of enrofloxacin in poultry to achieve higher maximal serum concentrations. The Veterinary Journal, 165, 143-148
34. Ter Hune, T. N., Wages, P.W., Swafford, W.S. and Tolling, S.T., 1991. Clinical evaluation of efficacy of danofloxacin treatment of E. coli airsacculitis. Proceedings of the 40th Western Poultry Disease Conference, 270
35. Toutain, P.L., 2003. Antibiotic treatment of animals - a different approach to rational dosing. The Veterinary Journal, 165, 98-100
36. Toutain, P.L. and Bousquet-Melou, A., 2002. Free drug fraction vs free drug concentration: A matter of frequent confusion. Journal of Veterinary Pharmacology and Therapeutics, 25, 460-463
37. Toutain, P.L., Del Castillo, J.R.E. and Bousquet-Melou, A., 2002. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 73, 105-114
38. Van Miert, A.S.J.P.A.M., 1991. Acute phase response and non cellular defence machanisms. Flemish Veterinary Journal, 62 (supplemenet 1), 69-91
39. Webber, M. and Piddock, L.J.V., 2001. Quinolone resistance in Escherichia coli. Veterinary Research, 32, 275-284
40. Wise, R., 2003. Maximizing efficacy and reducing the emergence of resistance. Journal of Antimicrobial Chemotherapy, 51 (supplement S1), 37-42
41. Wolfson, J.S. and Hooper, D.C., 1985. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy. 28, 581-586